Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma

BACKGROUND: We have previously shown that podocalyxin-like protein (PODXL) is a prognostic biomarker for poor survival in gastric and esophageal adenocarcinoma treated with surgery up-front. The aim of the present study was to assess PODXL expression in tumors from patients treated with neoadjuvant ...

Descripción completa

Detalles Bibliográficos
Autores principales: Borg, David, Larsson, Anna H., Hedner, Charlotta, Nodin, Björn, Johnsson, Anders, Jirström, Karin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201481/
https://www.ncbi.nlm.nih.gov/pubmed/30355278
http://dx.doi.org/10.1186/s12967-018-1668-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201481/
https://www.ncbi.nlm.nih.gov/pubmed/30355278
http://dx.doi.org/10.1186/s12967-018-1668-3

Ejemplares similares